Bellicum Pharmaceuticals, Inc.
BLCM
BLCM was delisted on the 1st of June, 2023.
30 hedge funds and large institutions have $5.13M invested in Bellicum Pharmaceuticals, Inc. in 2021 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 4 increasing their positions, 8 reducing their positions, and 3 closing their positions.
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
3% more funds holding
Funds holding: 29 → 30 (+1)
0% less capital invested
Capital invested by funds: $5.14M → $5.13M (-$14K)
50% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$717K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$87.5K |
| 3 |
State Street
Boston,
Massachusetts
|
+$87.4K |
| 4 |
LPL Financial
San Diego,
California
|
+$40.9K |
| 5 |
Morgan Stanley
New York
|
+$12.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$99K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$65.6K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
-$59K |
| 4 |
Bank of New York Mellon
New York
|
-$50K |
| 5 |
SFI
Susquehanna Fundamental Investments
Bala Cynwyd,
Pennsylvania
|
-$50K |
BLCM Hedge Fund Activity: Q2 2021 in Review
30 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Bellicum Pharmaceuticals, Inc. (BLCM) for Q2 2021, worth a combined $5.13M — down 0.27% from $5.14M a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new BLCM positions and 3 closed out — a net gain of 1 holder — while 4 added to existing stakes and 8 trimmed.
The largest buyer was Vanguard Group, adding an estimated $717K. The largest seller was BlackRock, cutting an estimated $99K.
- 30 institutional investors held Bellicum Pharmaceuticals, Inc. (BLCM) as of Q2 2021, up from 29 in Q1 2021.
- Funds reported $5.13M of Bellicum Pharmaceuticals, Inc. stock for Q2 2021, down 0.27% quarter-over-quarter.
- 4 funds opened new Bellicum Pharmaceuticals, Inc. positions in Q2 2021 and 3 closed out, a net change of +1 holder.
- The largest Bellicum Pharmaceuticals, Inc. buyer in Q2 2021 was Vanguard Group, an estimated $717K added.
- The largest Bellicum Pharmaceuticals, Inc. seller in Q2 2021 was BlackRock, an estimated $99K sold.
Based on aggregated 13F filings for Q2 2021.